Research methodEvidence overview
Evidence categories are kept distinct.
Human trials, official regulatory status, preclinical models, and batch documentation answer different questions and are labeled separately.
Research library
Evidence first. Claims second.
Research overviews for the compounds in the catalog, with clear separation between human trials, preclinical work, mechanistic interest, and unanswered questions.
Incretin pathway mapEvidence overview
Incretin status map
Approved indications, published human evidence, and investigational incretin programs represent separate evidence and regulatory stages.
Repair-biology modelEvidence overview
Repair-biology evidence map
Regenerative peptide literature often centers on matrix remodeling, fibroblast signaling, migration, and preclinical wound-healing models.
Cellular energy mapEvidence overview
Cellular-energy context
NAD+ research connects redox biology, mitochondrial function, and repair signaling, but biomarker movement is not the same as proven outcome benefit.
Research topic
GLP-1 / GLP-2 / “GLP-3”
Definitions and distinctions among GLP-1, GLP-2, and informal “GLP-3” shorthand.
Research topic
Incretin timeline
Semaglutide, tirzepatide, retatrutide, FDA milestones, and public-policy context.
Research topic
Human evidence
Pages that separate randomized human outcomes from mechanistic explanation.
Research topic
Ordering guide
A practical checklist for product details, documentation, pricing, shipping, and contact information.
SemaglutideResearch note 01
Semaglutide research: what the current human data actually shows.
Semaglutide has one of the strongest modern human evidence bases in this research-product class, with randomized trials reporting substantial weight and metabolic outcomes plus cardiovascular outcome data in selected populations.
Answers: What is semaglutide being studied for in the strongest published human data?
Read research noteTirzepatideResearch note 02
Tirzepatide research: why the dual-incretin data changed the conversation.
Tirzepatide brought unusually strong outcome data into the incretin conversation, with large human trials pushing magnitude beyond what earlier single-pathway agents had established.
Answers: Why do researchers pay so much attention to tirzepatide right now?
Read research noteRetatrutideResearch note 03
Retatrutide research: phase 2 evidence, phase 3 progress, and current status.
Retatrutide has published phase 2 human evidence, and Lilly reported three completed phase 3 trials by June 2026. It remains investigational and unapproved, with additional trials underway.
Answers: What is the current evidence and regulatory status of retatrutide?
Read research noteGLP terminologyResearch note 04
GLP-1, GLP-2, and “GLP-3”: what the terms actually mean.
GLP-1 and GLP-2 are established glucagon-like peptide terms. “GLP-3” is not a recognized human peptide category; it is an informal label sometimes applied to triple-agonist research such as retatrutide.
Answers: What do GLP-1, GLP-2, and “GLP-3” actually mean?
Read research noteIncretin timelineResearch note 05
Incretin regulatory timeline: approvals, evidence, and retatrutide status.
Semaglutide and tirzepatide appear in FDA-approved branded medicines for specific indications. Retatrutide remains investigational and unapproved, even as Lilly reports completed phase 3 trials.
Answers: What is the current FDA and research status of semaglutide, tirzepatide, and retatrutide?
Read research noteGHK-CuResearch note 06
GHK-Cu research: where the evidence is interesting and where it is still mostly preclinical.
GHK-Cu has a long history of regenerative and wound-healing interest, but much of the excitement still comes from preclinical and mechanistic literature rather than large modern human trials.
Answers: What does the literature really support for GHK-Cu right now?
Read research noteBPC-157Research note 07
BPC-157 research: wound-healing interest, animal data, and the human evidence gap.
BPC-157 has a large wound-healing and cytoprotection literature footprint, but most of the persuasive evidence remains preclinical rather than large, modern human trials.
Answers: What is the strongest evidence category for BPC-157 right now?
Read research noteTB-500 / Thymosin Beta-4Research note 08
TB-500 research: thymosin beta-4 biology and tissue-repair questions.
TB-500 is discussed as a synthetic thymosin beta-4-related research peptide, but the strongest literature is better understood through thymosin beta-4 biology than finished human outcomes.
Answers: What is TB-500 research actually based on?
Read research noteNAD+Research note 09
NAD+ research: human precursor trials, aging biology, and realistic expectations.
NAD+ biology is central to metabolism and aging research, but human trial interpretation needs care because precursor supplementation, NADH, and NAD+ itself are often blended together online.
Answers: What do human studies say about NAD+ and NAD+-boosting compounds?
Read research noteMelanotan IIResearch note 10
Melanotan II research: melanocortin biology, pigmentation, and safety questions.
Melanotan II sits in the melanocortin receptor literature, with research touching pigmentation and sexual-function pathways, but safety concerns and online misuse make careful framing essential.
Answers: What is Melanotan II research actually about?
Read research note